SRPK1 and breast cancer: Therefore, targeting the PTMs and kinase activity of SRPK1 has the potential to re-sensitize breast cancer cells to chemotherapy, and this strategy has the advantage of being titratable and reversible as compared with other approaches, such as genetic manipulation.